PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease. We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions. METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients. We used enzyme-linked immunosorbent assay (ELISA) to confirm one of these markers in an additional validation set of 101 cases. RESULTS: Approximately 80 CSF proteins were identified and found to be present at significantly different concentrations, both higher and lower, in training and test studies, which were highly concordant. To further validate these observations, we defined in detail the expression of one of these candidate biomarkers, antithrombin III (ATIII). ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature. Determination of ATIII concentration by ELISA was significantly more accurate (> 75% sensitivity; > 98% specificity) than cytology in the identification of cancer. Measurement of CSF ATIII levels was found to potentially enhance the ability to diagnose and predict outcome. CONCLUSION: Our findings demonstrate for the first time that proteomic analysis of CSF yields individual biomarkers with greater sensitivity in the identification of cancer than does CSF cytology. We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease. We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions. METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients. We used enzyme-linked immunosorbent assay (ELISA) to confirm one of these markers in an additional validation set of 101 cases. RESULTS: Approximately 80 CSF proteins were identified and found to be present at significantly different concentrations, both higher and lower, in training and test studies, which were highly concordant. To further validate these observations, we defined in detail the expression of one of these candidate biomarkers, antithrombin III (ATIII). ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature. Determination of ATIII concentration by ELISA was significantly more accurate (> 75% sensitivity; > 98% specificity) than cytology in the identification of cancer. Measurement of CSF ATIII levels was found to potentially enhance the ability to diagnose and predict outcome. CONCLUSION: Our findings demonstrate for the first time that proteomic analysis of CSF yields individual biomarkers with greater sensitivity in the identification of cancer than does CSF cytology. We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
Authors: Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta Journal: Lancet Date: 2002-02-16 Impact factor: 79.321
Authors: J Y Blay; T Conroy; C Chevreau; A Thyss; N Quesnel; H Eghbali; R Bouabdallah; B Coiffier; J P Wagner; A Le Mevel; D Dramais-Marcel; E Baumelou; F Chauvin; P Biron Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: Meena U Rajagopal; Yetrib Hathout; Tobey J MacDonald; Mark W Kieran; Sri Gururangan; Susan M Blaney; Peter Phillips; Roger Packer; Heather Gordish-Dressman; Brian R Rood Journal: Proteomics Date: 2011-01-27 Impact factor: 3.984
Authors: Chi-Chao Chan; James L Rubenstein; Sarah E Coupland; Janet L Davis; J William Harbour; Patrick B Johnston; Nathalie Cassoux; Valerie Touitou; Justine R Smith; Tracy T Batchelor; Jose S Pulido Journal: Oncologist Date: 2011-11-01
Authors: Emmanuelle Mouton-Barbosa; Florence Roux-Dalvai; David Bouyssié; François Berger; Eric Schmidt; Pier Giorgio Righetti; Luc Guerrier; Egisto Boschetti; Odile Burlet-Schiltz; Bernard Monsarrat; Anne Gonzalez de Peredo Journal: Mol Cell Proteomics Date: 2010-01-21 Impact factor: 5.911
Authors: M C Mabray; R F Barajas; J E Villanueva-Meyer; C A Zhang; F E Valles; J L Rubenstein; S Cha Journal: AJNR Am J Neuroradiol Date: 2015-09-17 Impact factor: 3.825
Authors: Wei-Jun Qian; Tao Liu; Vladislav A Petyuk; Marina A Gritsenko; Brianne O Petritis; Ashoka D Polpitiya; Amit Kaushal; Wenzhong Xiao; Celeste C Finnerty; Marc G Jeschke; Navdeep Jaitly; Matthew E Monroe; Ronald J Moore; Lyle L Moldawer; Ronald W Davis; Ronald G Tompkins; David N Herndon; David G Camp; Richard D Smith Journal: J Proteome Res Date: 2009-01 Impact factor: 4.466